These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 16915301)
1. Does eplerenone have a future in the management of hypertension in Europe? Gosse P; Macfadyen RJ J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301 [No Abstract] [Full Text] [Related]
2. Ethics and eplerenone. Gupta S; Fugh-Berman AJ; Scialli A J Med Ethics; 2013 Feb; 39(2):110-4. PubMed ID: 23015747 [TBL] [Abstract][Full Text] [Related]
3. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Karagiannis A; Athyros VG; Mikhailidis DP Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701 [No Abstract] [Full Text] [Related]
4. Eplerenone after myocardial infarction? Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726 [TBL] [Abstract][Full Text] [Related]
5. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Moore TD; Nawarskas JJ; Anderson JR Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934 [TBL] [Abstract][Full Text] [Related]
6. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876 [TBL] [Abstract][Full Text] [Related]
7. Eplerenone is not superior to older and less expensive aldosterone antagonists. Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667 [TBL] [Abstract][Full Text] [Related]
12. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Barnes BJ; Howard PA Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. de Pouvourville G; Solesse A; Beillat M Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935 [TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747 [TBL] [Abstract][Full Text] [Related]
18. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Funder JW Am Heart J; 2002 Nov; 144(5 Suppl):S8-11. PubMed ID: 12422135 [No Abstract] [Full Text] [Related]
19. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Struthers A; Krum H; Williams GH Clin Cardiol; 2008 Apr; 31(4):153-8. PubMed ID: 18404673 [TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review. Flatt DM; Brown MC; Mizeracki AM; King BJ; Weber KT JAMA Cardiol; 2016 Aug; 1(5):607-12. PubMed ID: 27434136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]